Frontiers in Psychiatry
July 25, 2022
Maximilian Carter, Kassandra Solsrud, Nicholas Mischel
IntroductionAbout one third of patients with major depressive disorder (MDD) have treatment resistant depression (TRD). The difficulty of treating TRD especially in those with suicidal ideation and psychotic features demands treatments that are fast-acting, safe, and effective. Limited access, lack of viable options, and incomplete characterization of rapid-acting antidepressants has prevented...
Frontiers in Pharmacology
July 25, 2022
Kurt Stocker, Matthias Hartmann, Steffen Reissmann et al.
Background: Cognition that is not dominated by thinking in terms of opposites (opposite diminishing) or by making judgments (non-judging) can be found both in Buddhist/mindfulness contexts and in mental states that are fostered by dissociative psychedelics (N-methyl-D-aspartate antagonists) such as ketamine. Especially for the Buddhist/mindfulness case, both opposite diminishing and non-judging...
Frontiers in Psychiatry
July 22, 2022
M. Cigognini, A. G. Guirado, Denise van de Meene et al.
Objective Ketamine, an N-methyl D-aspartate (NMDA) receptor antagonist, can promote rapid action in the management of individuals with treatment-resistant depression (TRD) at sub-anesthetic doses. However, few studies have investigated the long-term use of ketamine administered intravenously (IV) and intranasally (IN). We report the design and rationale of a therapeutic trial for assessing the...
Frontiers in Psychiatry
July 22, 2022
Lai Fong Chan, Luke Sy-Cherng Woon, Nuur Asyikin Mohd Shukor et al.
2 citations
A significant proportion of patients with treatment-resistant depression do not attain functional recovery despite administration of multiple steps of pharmacotherapeutic strategies. This highlights the elusiveness of meeting unmet needs in existing pharmacotherapies for treatment-resistant depression. There is accumulating evidence that antidepressant agents involving the glutamatergic system...
Frontiers in Psychiatry
July 8, 2022
Maud Rothärmel, Cherifa Benosman, Wissam El-Hage et al.
31 citations
Introduction: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in patients having TRD with comorbid PTSD. Materials and...
Frontiers in Pharmacology
July 7, 2022
Songbai Xu, Xiaoxiao Yao, Bingjin Li et al.
50 citations
Major depressive disorder (MDD) is a devastating psychiatric disorder which exacts enormous personal and social-economic burdens. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has been discovered to exert rapid and sustained antidepressant-like actions on MDD patients and animal models. However, the dissociation and psychotomimetic propensities of ketamine have limited its use...
The World Journal of Biological Psychiatry
July 4, 2022
Monika Dmitrzak-Weglarz, M. Tyszkiewicz-Nwafor, Filip Rybakowski et al.
Abstract Objectives This study attempts to assess the concentration of two opposite-acting adipokines (anti-inflammatory adiponectin and pro-inflammatory resistin) in antidepressant-resistant patients undergoing ketamine infusion (KI) and electroconvulsive therapy (ECT). Methods The study group comprised 52 patients hospitalised due to episodes of depression in the course of bipolar disorders....
Neuron
July 1, 2022
Li Ma, Kenji Hashimoto
In this issue of Neuron, Lopez et al. report that KCNQ2 (potassium voltage-gated channel subfamily Q member 2) is essential for the sustained antidepressant-like effects of ketamine in glutamatergic neurons of the ventral hippocampus. This study implies that KCNQ2 activators can be novel antidepressants without the ketamine side effects.
Psychiatry Research
July 1, 2022
Mu-Hong Chen, Chih-Ming Cheng, Cheng-Ta Li et al.
BACKGROUND This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD). METHODS In the ketamine infusion trial, 48 patients with TRD were randomized to receive a single infusion of 0.5 mg/kg ketamine or normal saline. In the rTMS trial, 105...
Psychopharmacology
July 2022
Hildegard A Wulf, Caroline A Browne, Carlos A. Zarate et al.
Emerging evidence has implicated the endogenous opioid system in mediating ketamine's antidepressant activity in subjects with major depressive disorder. To date, mu opioid receptors have been suggested as the primary opioid receptor of interest. However, this hypothesis relies primarily on observations that the opioid antagonist naltrexone blocked the effects of ketamine in humans and rodents....